Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Current Assets (2016 - 2025)

vTv Therapeutics' Current Assets history spans 12 years, with the latest figure at $99.5 million for Q3 2025.

  • For Q3 2025, Current Assets rose 131.52% year-over-year to $99.5 million; the TTM value through Sep 2025 reached $99.5 million, up 131.52%, while the annual FY2024 figure was $38.1 million, 257.63% up from the prior year.
  • Current Assets for Q3 2025 was $99.5 million at vTv Therapeutics, up from $26.4 million in the prior quarter.
  • Across five years, Current Assets topped out at $99.5 million in Q3 2025 and bottomed at $9.2 million in Q1 2021.
  • The 5-year median for Current Assets is $26.4 million (2025), against an average of $29.1 million.
  • The largest annual shift saw Current Assets soared 502.8% in 2021 before it plummeted 64.82% in 2023.
  • A 5-year view of Current Assets shows it stood at $15.6 million in 2021, then skyrocketed by 73.45% to $27.1 million in 2022, then tumbled by 60.67% to $10.7 million in 2023, then skyrocketed by 257.63% to $38.1 million in 2024, then soared by 160.95% to $99.5 million in 2025.
  • Per Business Quant, the three most recent readings for VTVT's Current Assets are $99.5 million (Q3 2025), $26.4 million (Q2 2025), and $31.9 million (Q1 2025).